Neptune Wellness Solutions Stock (NASDAQ:NEPT)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.20

52W Range

$0.20 - $0.25

50D Avg

-

200D Avg

-

Market Cap

$906.41K

Avg Vol (3M)

$393.84K

Beta

2.19

Div Yield

-

NEPT Company Profile


Neptune Wellness Solutions Inc. operates as an integrated health and wellness company in Canada, the United States, and internationally. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, MaxSimil, and NurturMe brands. The company also offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, including nutraceuticals, beauty and personal care products, and organic foods and beverages. In addition, it is involved in the extraction, purification, formulation, and manufacturing of health and wellness products. Further, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

50

IPO Date

Aug 13, 2007

Website

NEPT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 21
Nutraceutical Products$16.11M
Processing Services$11.11M
Innovation Products$14.49M
Cannabis And Hemp Products$416.30K
Food And Beverages Products$3.18M

Fiscal year ends in Mar 23 | Currency in USD

NEPT Financial Summary


Mar 23Mar 22Mar 21
Revenue$71.11M$61.01M$44.49M
Operating Income$-66.74M$-87.49M$-119.61M
Net Income$-81.71M$-93.73M$-154.80M
EBITDA$-63.05M$-79.89M$-95.65M
Basic EPS$-276.70$-777.15$-1.79K
Diluted EPS$-276.70$-777.15$-1.79K

Fiscal year ends in Mar 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Nov 16, 23 | 1:55 PM
Q3 23Mar 31, 23 | 6:14 PM
Q2 23Dec 16, 22 | 6:54 PM

Peer Comparison


TickerCompany
SNOASonoma Pharmaceuticals, Inc.
AKANAkanda Corp.
BFRIBiofrontera Inc.
FLGCFlora Growth Corp.
TKNOAlpha Teknova, Inc.
ACORAcorda Therapeutics, Inc.
SBFMSunshine Biopharma, Inc.
ESPREsperion Therapeutics, Inc.
PAHCPhibro Animal Health Corporation
UPCUniverse Pharmaceuticals INC
GHSIGuardion Health Sciences, Inc.
ALIMAlimera Sciences, Inc.
SSICSilver Spike Investment Corp.
CLVRClever Leaves Holdings Inc.
JUPWSafety Shot Inc
SXTCChina SXT Pharmaceuticals, Inc.
IMCCIM Cannabis Corp.
EGRXEagle Pharmaceuticals, Inc.